Marker Therapeutics (MRKR)

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

The Marker Therapeutics, Inc. Common Stock (MRKR) stock price today is $1.40, reflecting a -1.76% move since the market opened. The company’s market capitalization stands at $23.26M, with a daily trading volume of $35.88K shares. For investors tracking price trends, Marker Therapeutics, Inc. Common Stock stock has ranged between $1.40 and $1.40 today. The previous closing price was $1.42.

Ready to get started? Follow the steps below, or read our guide on how to buy Marker Therapeutics stock on Kraken starting from $10.